Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer

Rulach, R. J. et al. (2018) Real world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU International, 121(2), pp. 268-274. (doi:10.1111/bju.14025) (PMID:28940952)

[img]
Preview
Text
148743.pdf - Accepted Version

1MB

Abstract

Objectives: To investigate the uptake, safety and efficacy of docetaxel chemotherapy in hormone-naïve metastatic prostate cancer (mPC) in the first year of use outside of a clinical trial. Subjects/patients and Methods: Patients in the West of Scotland Cancer Network (WoSCAN) with newly diagnosed mPC were identified from the regional multidisciplinary team (MDT) meetings and their treatment details were collected from electronic patient records. The rate of febrile neutropenia, hospitalisations, time to progression and overall survival were compared between those patients who received docetaxel and androgen deprivation therapy (ADT), or ADT alone using survival analysis. Results: Out of 270 eligible patients, 103 received docetaxel (38.1%). 35 patients (34%) were hospitalised and there were 17 episodes of febrile neutropenia (16.5%). Two patients (1.9%) died within 30 days of chemotherapy. Patients who received ADT alone had an increased risk of progression (HR 2.03, 95% CI (1.27, 3.25), log-rank test, p= 0.002) and had an increased risk of death (HR 5.88, 95% CI 2.52, 13.72, log-rank p=0.001) compared to the docetaxel group. The risk of febrile neutropenia was nine times greater if chemotherapy was started within three weeks of ADT initiation (95% CI (1.22,77.72) p= 0.032). Conclusion: Docetaxel chemotherapy in hormone-naïve mPC has significant toxicities, but has a similar effect on time to progression and overall survival as seen in randomised trials. Chemotherapy should be started 3 weeks or more after androgen deprivation.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Russell, Dr Martin and Glen, Dr Hilary and Carruthers, Dr Ross and Venugopal, Dr Bala and Jones, Professor Robert
Authors: Rulach, R. J., McKay, S., Neilson, S., White, L., Wallace, J., Carruthers, R., Lamb, C., Cascales, A., Marashi, H., Glen, H., Venugopal, B., Sadoyze, A., Sidek, N., Russell, J. M., Alhasso, A., Dodds, D., Laskey, J., Jones, R. J., and MacLeod, N.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:BJU International
Publisher:Wiley
ISSN:1464-4096
ISSN (Online):1464-410X
Published Online:20 September 2017
Copyright Holders:Copyright © 2017 The Authors and BJU International
First Published:First published in BJU International 121(2):268-274
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record